LOC: HIV Prevention Trials Network

描述(由申请人提供)：艾滋病毒预防试验网络(HPTN)的任务是进行研究，旨在确定艾滋病毒预防干预措施的最佳组合，以防止艾滋病毒感染在感染风险最高的人群中传播。HPTN将由哥伦比亚大学的Wafaa Ei-Sadr博士和北卡罗来纳大学教堂山分校的Myron S.Cohen博士领导，并得到经验丰富的运营、实验室、统计和数据中心的支持。HPTN将处理和支持两个研究优先领域，以实现以下八个具体目标：优先领域1的具体目标：预防艾滋病毒感染的综合战略：目标1：制定预防南部非洲年轻妇女感染艾滋病毒的综合战略；目标2：制定预防男男性行为者(MSM)感染艾滋病毒的综合战略；分目标2a：确定预防美洲未感染艾滋病毒的男男性行为者和变性妇女感染艾滋病毒的综合战略；分目标2b：确定预防美国感染艾滋病毒的男男性行为者感染艾滋病毒的综合战略；目标3：制定一项预防东欧和亚洲注射吸毒者感染艾滋病毒的综合战略；目标4：实施一项综合战略，几乎消除(1%)撒哈拉以南非洲不和睦夫妇中艾滋病毒的传播；目标5：制定方法，使男男性行为者参与预防研究，为制定预防这一人群中艾滋病毒感染的综合战略铺平道路。重点领域2：暴露前预防：目标6：评价含有马拉韦罗(MVC)的抗逆转录病毒疗法对预防艾滋病的疗效；目标7：开发具有良好特性的PrEP新药物，包括长效药物；目标8：开发药物统计学模型以确定PrEP新药物的作用。

DESCRIPTION (provided by applicant): The mission of the HIV Prevention Trials Network (HPTN) is to conduct research designed to identify the best combinations of HIV prevention interventions to prevent HIV infection in populations at the highest risk for this infection. The HPTN will be led by Drs. Wafaa EI-Sadr, Columbia University, and Myron S. Cohen, University of North Carolina at Chapel Hill, and supported by experienced operations, laboratory and statistical and data centers. The HPTN will address and support the two research Priority Areas in order to achieve the following eight Specific Aims: Specific Aims for Priority Area 1: Integrate Strategies to Prevent HIV Infection: Aim 1: To develop an integrated strategy to prevent HIV infection in young women in Southern Africa; Aim 2: To develop integrated strategies to prevent HIV infection in men who have sex with men (MSM); Sub-aim 2a: To identify an integrated strategy to prevent HIV acquisition in HIV-uninfected MSM and transgender women in the Americas; Sub-aim 2b: To identify an integrated strategy to prevent HIV transmission from HIV-infected MSM in the United States (U.S.); Aim 3: To develop an integrated strategy to prevent HIV infection in injection drug users (IDUs) in Eastern Europe and Asia; Aim 4: To implement an integrated strategy to virtually eliminate (<1%) HIV transmission in discordant couples in sub-Saharan Africa {SSA}; Aim 5: To develop methods to engage MSM in SSA in prevention research, paving the way for development of an integrated strategy to prevent HIV infection in this population Specific Aims for Priority Area 2: Pre-exposure Prophylaxis {PrEP}: Aim 6: To evaluate the efficacy of an ARV regimen containing maraviroc (MVC) for PrEP; Aim 7: To develop new agents for PrEP with favorable profiles, including long lasting agents; Aim 8: To develop pharmacostatistical models to define the role of new agents for PrEP.